Exploring the Science and Appreciating the Patient Experience: Early, Individualized Therapy to Optimize Outcomes in Multiple Sclerosis

Monday, October 14, 2019
6:00 AM – 7:30 AM
Landmark 5
Marriott St. Louis Grand
800 Washington Avenue
St. Louis, MO 63101

 

AGENDA

6:00 AM – 6:30 AM      Registration/Breakfast Served
6:30 AM – 7:15 AM      Practitioner’s EdgeSM  Scientific Session
7:15 AM – 7:30 AM      Question & Answer Session/Closing Remarks

PRACTITIONER’S EDGESM PANEL

Aaron L. Boster, MD
Systems Medical Chief, Neuroimmunology
OhioHealth Neurological Physicians
Columbus, Ohio

Claire S. Riley, MD
Assistant Professor of Neurology
Clinical Director, Multiple Sclerosis Center
Columbia University Medical Center
New York, New York

PROGRAM OVERVIEW

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this interactive case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making.

PROGRAM FORMAT

Practitioner’s EdgeSM Workshops are innovative, interactive meetings that provide attendees with cutting edge medical education in a peer-to-peer discussion setting. Practitioner’s EdgeSM provides the practicing healthcare provider with tools and education that may be utilized immediately in daily practice.

In this Practitioner’s EdgeSM program, case studies will be utilized to illustrate issues related to patients with MS. Audience participation will be invited via interactive questions interspersed throughout the program. The results of the interactive questions will serve as a catalyst for faculty discussion and best-practice reinforcement.

TARGET AUDIENCE

This educational initiative has been designed for MS specialists, neurologists, internists, and allied healthcare professionals in MS centers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe current perspectives regarding early, efficacious treatment of active MS disease to prevent irreversible neurologic damage
  • Compare the mechanisms of action and efficacy of currently available and emerging MS treatments in order to better individualize patient treatment plans
  • Design therapeutic strategies encompassing patient efficacy outcomes, safety and tolerability considerations, reimbursement strategies and consideration, as well as patient preferences, when selecting a DMT
  • Implement a multidisciplinary treatment strategy involving shared decision-making along with appropriate patient resources to improve the management of patients with MS
REGISTRATION

There is no registration fee for attending this symposium; however, seating is limited. To register, click the button at the top right of this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.  Preregistration does not guarantee seating. We recommend arriving at the meeting location early.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live event.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

This symposium is not part of the ANA official educational program and the session and content are not endorsed by ANA.

 

Provided by Integrity Continuing Education, Inc.

Supported by independent educational grants from Biogen MA, Inc. and Novartis Pharmaceuticals Corporation. This activity was supported by an educational grant from Celgene Corporation.

 

Agenda

6:00 AM – 6:30 AM       Registration/Breakfast Served

6:30 AM – 7:15 AM       Practitioner’s EdgeSM  Scientific Session

7:15 AM – 7:30 AM       Question & Answer Session/Closing Remarks